These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 23796292)

  • 1. QALY and productivity loss: empirical evidence for "double counting".
    Shiroiwa T; Fukuda T; Ikeda S; Shimozuma K
    Value Health; 2013 Jun; 16(4):581-7. PubMed ID: 23796292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vision and quality-of-life.
    Brown GC
    Trans Am Ophthalmol Soc; 1999; 97():473-511. PubMed ID: 10703139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs and quality of life of multiple sclerosis in Switzerland.
    Kobelt G; Berg J; Lindgren P; Gerfin A; Lutz J
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S86-95. PubMed ID: 17310338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs and quality of life in multiple sclerosis in The Netherlands.
    Kobelt G; Berg J; Lindgren P; Anten B; Ekman M; Jongen PJ; Polman C; Uitdehaag B
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S55-64. PubMed ID: 17310343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costs and quality of life of multiple sclerosis in Italy.
    Kobelt G; Berg J; Lindgren P; Battaglia M; Lucioni C; Uccelli A
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S45-54. PubMed ID: 17310336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Costs and quality of life of multiple sclerosis in Spain.
    Kobelt G; Berg J; Lindgren P; Izquierdo G; Sánchez-Soliño O; Pérez-Miranda J; Casado MA;
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S65-74. PubMed ID: 17310340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of living with a functional and aesthetic nasal deformity after primary rhinoplasty: a utility outcomes score assessment.
    Sinno H; Izadpanah A; Thibaudeau S; Christodoulou G; Tahiri Y; Slavin SA; Lin SJ
    Ann Plast Surg; 2012 Oct; 69(4):431-4. PubMed ID: 22964667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs and quality of life of multiple sclerosis in Austria.
    Kobelt G; Berg J; Lindgren P; Plesnilla C; Baumhackl U; Berger T; Kolleger H; Vass K
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S14-23. PubMed ID: 17310339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does the EQ-5D reflect lost earnings?
    Tilling C; Krol M; Tsuchiya A; Brazier J; Exel Jv; Brouwer W
    Pharmacoeconomics; 2012 Jan; 30(1):47-61. PubMed ID: 22066754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing utility values in rheumatoid arthritis: a comparison between time trade-off and the EuroQol.
    Ariza-Ariza R; Hernández-Cruz B; Carmona L; Dolores Ruiz-Montesinos M; Ballina J; Navarro-Sarabia F;
    Arthritis Rheum; 2006 Oct; 55(5):751-6. PubMed ID: 17013822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costs and quality of life for patients with multiple sclerosis in Belgium.
    Kobelt G
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S24-33. PubMed ID: 17318662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breaking the silence: exploring the potential effects of explicit instructions on incorporating income and leisure in TTO exercises.
    Krol M; Sendi P; Brouwer W
    Value Health; 2009; 12(1):172-80. PubMed ID: 18647262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do quality-adjusted life years take account of lost income? Evidence from an Australian survey.
    Richardson J; Peacock SJ; Iezzi A
    Eur J Health Econ; 2009 Feb; 10(1):103-9. PubMed ID: 18458973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costs and quality of life of multiple sclerosis in Germany.
    Kobelt G; Berg J; Lindgren P; Elias WG; Flachenecker P; Freidel M; König N; Limmroth V; Straube E
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S34-44. PubMed ID: 17310337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is silence golden? A test of the incorporation of the effects of ill-health on income and leisure in health state valuations.
    Sendi P; Brouwer WB
    Health Econ; 2005 Jun; 14(6):643-7. PubMed ID: 15678519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost effectiveness of single-level instrumented posterolateral lumbar fusion at 5 years after surgery.
    Glassman SD; Polly DW; Dimar JR; Carreon LY
    Spine (Phila Pa 1976); 2012 Apr; 37(9):769-74. PubMed ID: 20489676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of subjective life expectancy on health state valuations using a 10 year TTO.
    van Nooten FE; Koolman X; Brouwer WB
    Health Econ; 2009 May; 18(5):549-58. PubMed ID: 18702082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sagittal craniosynostosis: a utility outcomes study.
    Kuta V; McNeely PD; Walling S; Bezuhly M
    J Neurosurg Pediatr; 2017 Aug; 20(2):113-118. PubMed ID: 28524791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of non-severe hypoglycemic events on work productivity and diabetes management.
    Brod M; Christensen T; Thomsen TL; Bushnell DM
    Value Health; 2011; 14(5):665-71. PubMed ID: 21839404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.